蔚蓝生物 (603739.SH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1.4B	1.4B	1.3B	1.2B	1.2B
Cost of Revenue	774.0M	754.2M	725.8M	644.7M	660.3M
Gross Profit	627.0M	612.0M	595.0M	554.2M	502.9M
Operating Expenses
R&D Expense	140.9M	139.2M	118.2M	110.7M	102.4M
SG&A Expense	—	—	—	—	—
General & Admin Expense	152.9M	150.9M	146.6M	124.8M	120.8M
Selling & Marketing Expense	202.9M	202.2M	197.4M	189.7M	176.8M
Other Expenses	—	—	—	—	—
Total Operating Expenses	532.5M	527.1M	496.2M	449.2M	414.6M
Cost and Expenses	1.3B	1.3B	1.2B	1.1B	1.1B
Operating Income (EBIT)	135.2M	127.6M	124.0M	122.9M	102.9M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	131.6M	123.7M	123.4M	122.5M	102.2M
Income Tax Expense	25.2M	26.2M	31.3M	19.6M	16.8M
Bottom Line
Net Income	78.1M	69.8M	62.6M	80.7M	69.8M
Earnings from Cont. Ops	106.3M	97.5M	92.2M	102.9M	85.4M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	78.1M	69.8M	62.6M	80.7M	69.8M
Per Share
Basic EPS	CN¥0.31	CN¥0.28	CN¥0.25	CN¥0.32	CN¥0.28
Diluted EPS	CN¥0.31	CN¥0.28	CN¥0.25	CN¥0.32	CN¥0.27
Revenue Per Share	CN¥5.49	CN¥5.48	CN¥5.27	CN¥4.75	CN¥4.66
Shares
Basic Shares Outstanding	255.3M	249.3M	250.5M	252.2M	249.4M
Diluted Shares Outstanding	255.3M	249.3M	250.5M	252.2M	249.4M
Profitability Metrics
EBITDA	—	245.8M	236.2M	197.2M	169.6M
D&A	—	118.2M	112.2M	74.3M	66.7M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026